Abstract:Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that possesses both lipid and protein phosphatase activities. The main function of PTEN is to block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate to PI-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent event in many cancer types and can occur through various genetic alterations including point mutations, large chromosomal deletions, and epigenetic mechanisms. In colorectal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms (typically: mutations and promoter hypermethylation or 10q23 LOH and promoter hypermethylation), which lead to the biallelic inactivation of the protein in 20-30% of cases. The role of PTEN as a prognostic and predictive factor in CRC has been addressed by relatively few works. This review is focused on the report and on the discussion of the studies investigating these aspects. Overall, at the moment, there are conflicting results and, therefore it has not been clarified whether PTEN might play a prognostic role in CRC. The same is valid also for the predictive role, leading to the fact that PTEN evaluation cannot be used in routinely diagnosis for the early identification of patients who might be addressed to the treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging to EGFR-downstream pathways. The reason of discordant results may be attributable to several issues: (1) the size of the analyzed cohort, (2) patients inclusion criteria, (3) the methods of assessing PTEN alteration. In particular, there are no standardized methods to evaluate this marker, especially for immunohistochemistry, a technique suffering of intra and inter-observer variability due to the semi-quantitative character of such an analysis. In conclusion, much work, especially in large and homogeneous cohorts of cases from different laboratories, has to be done before the establishment of PTEN as prognostic or predictive marker in CRC.

Regulatory Mechanisms of PTEN

Regulation of the tumor suppressor PTEN by natural anticancer compounds

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

Decoding PTEN: from biological functions to signaling pathways in tumors

Chemical and structural approaches to investigate PTEN function and regulation

Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal Phosphorylation

Targeting PTEN Regulation by Post Translational Modifications

PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

PTEN-Associated Complexes: An Overview.

PTEN regulation by Akt-EGR1-ARF-PTEN axis.

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

Astrocytic phosphatase and tensin homolog deleted on chromosome 10 regulates neuropathic pain by facilitating 3-hydroxy-3-methylglutaryl-CoA reductase–dependent cholesterol biosynthesis

PTEN, a General Negative Regulator of Cyclin D Expression

Functions and Regulation of the PTEN Gene in Colorectal Cancer

The structural basis of PTEN regulation by multi-site phosphorylation

Pten Acetylation Modulates Its Interaction With Pdz Domain

The Interplay Of Phosphorylation And Ubiquitylation In The Regulation Of Pten

PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription

PTEN in Chromatin Remodeling.